Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and pharmacokinetic study of respiratory syncytial virus fusion inhibitor GS-5806

Trial Profile

Safety and pharmacokinetic study of respiratory syncytial virus fusion inhibitor GS-5806

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Presatovir (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 17 Apr 2018 Results of pooled data from two phase 1 trial, were published in the Journal of Clinical Pharmacology.
    • 07 Oct 2014 New trial record
    • 06 Sep 2014 Results presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top